Ampio Pharmaceuticals: 3 Things to Know Before 2014

It's been a volatile but rewarding year for Ampio Pharmaceuticals   (NYSEMKT: AMPE  ) , a development-stage biotech best known for Optina, an oral treatment for two eye conditions caused by diabetes, and Ampion, a nonsteroid drug for inflammatory conditions. Both drugs are currently in phase 3 trials.

Ampio stock has rallied more than 100% over the past year on considerable optimism regarding both treatments.

AMPE Chart

Source: Ycharts

Let's take a look at three key things investors should know about Ampio going into 2014, and how larger companies like Roche Holding  (NASDAQOTH: RHHBY  ) , Novartis  (NYSE: NVS  ) , Regeneron Pharmaceuticals  (NASDAQ: REGN  ) , and Sanofi  (NYSE: SNY  ) fit into the company's overall outlook.

1. Optina keeps the needles away from the eyes
Ampio's Optina is a low-dose version of danazol, a generic steroid previously used to treat the gynecological condition endometriosis. Danazol was discovered to be able to prevent the leakage of small blood vessels, indicating that it had possible applications in diabetic eye conditions.

Optina attempts to treat damaged blood vessels in the retina (diabetic retinopathy) and blood vessels leaking into the macula (diabetic macular edema, or DME). Both conditions are leading causes of permanent blindness in diabetics.

Diabetic retinopathy and DME respectively affect approximately 60% and 10% of all diabetics. Analysts estimate that if approved, Optina could generate annual peak sales of $500 million on its DME indication alone. Optina is currently near the end of a 450 patient phase 3 trial, which could lead to a NDA (new drug application) being submitted next year. The trial tests patient's visual acuity when administered with Optina versus a placebo.

Optina has game-changing potential since it could be the first oral treatment for DME, compared to current treatment options that require injections into the eye.

Roche/Novartis' Lucentis is the only approved treatment for DME, although Roche's Avastin is also frequently prescribed as a cheaper, off-label alternative. A third treatment, Regeneron's Eylea, is expected to be approved for DME soon as well.

All three treatments are anti-VEGF (anti-vascular endothelial growth factor) drugs, which prevent new blood vessel growth, rather than stop the leakage of existing ones. Eylea and Lucentis are also approved for wet AMD (age macular degeneration), a similar condition to DME that isn't directly caused by diabetes. Avastin is also prescribed as an off-label treatment for wet AMD.

Ampio will have to be very careful with Optina's pricing when it hits the market, due to the vast difference between the costs of Lucentis, Eylea, and Avastin.


DME treatment

DME Status





(FDA and EU)




Off-label use




Phase 3


Source: Industry websites

Therefore, even though Optina will be an attractive, needle-free treatment for early stage DME, Avastin, which is still used in 67% of all intravitreal (IVT) treated DME patients, could force Ampio to lower its price for Optina to break into the market.

But Optina might be prescribed as an accompanying treatment for Lucentis or Avastin instead.

2. Reining in blockbuster expectations for Ampion
Ampion, Ampio's second lead drug candidate, is being tested as a treatment for osteoarthritis of the knee.

Ampion is currently in a phase 3 trial with 329 patients, which tests the drug against Sanofi's Synvisc-One, a commonly used injected treatment. According to interim data, patients on Ampion reported a 40% reduction in pain compared to 37% in the Synvisc-One arm.

While those results are encouraging, it's important to note that Synvisc-One, which was approved in the EU in 2008 and the US in 2009, isn't a blockbuster by any means. For the first nine months of 2013, Sanofi only reported $372 million in Synvisc-One sales -- a mere 3.3% increase from the previous year. That figure seemingly contradicts the peak sales estimate of $1 billion that analysts expect from Ampion.

Ampion could have a tough time achieving blockbuster status as a treatment for osteoarthritis of the knee alone, but I believe that its other possible applications -- for allergic rhinitis, multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases -- could unlock its true growth potential.

In addition, Ampio is developing an oral version of Ampion alongside its injected one. For rheumatoid and psoriatic arthritis, a generic oral drug known as methotrexate is usually administered first, which eventually escalates into an injected version. When injected methotrexate fails, more potent (and expensive) anti-TNF drugs such as Johnson & Johnson/Merck's Remicade, Amgen's Enbrel, and AbbVie's Humira are administered.

This means that oral Ampion could theoretically become a viable first-line treatment for some of these other inflammatory conditions. At this point, however, any other indications are pure speculation and highly dependent on an initial approval for osteoarthritis.

3. Additional offerings could cause volatility
Ampio hasn't generated any significant revenues since being founded in December 2008. Since then, it has incurred net losses of $56.2 million and finished last quarter with $32.1 million in cash and no debt.

Ampio has sold additional common stock over the past three years, raising $19.4 million, $15.4 million, and $29.0 million in 2011, 2012, and 2013, respectively. Those additional offerings caused considerable volatility for the stock over the past three years.

AMPE Cash and Equivalents (Quarterly) Chart


Ampio once had a third major drug, the sexual dysfunction medication Zertane, but spun it off into a stand-alone company called Vyrix Pharmaceuticals earlier this month.

Vyrix is expected to go public in about a year. The IPO could significantly boost Ampio's cash position, since the company intends to retain a 50% to 80% stake in the new venture.

The Foolish bottom line
In closing, Ampio will be a volatile stock in 2014, but there are four major catalysts for investors to look for:

  • The market approval of Optina for DME.

  • The market approval of Ampion for osteoarthritis of the knee.

  • A larger marketing partner for either drug, which would inspire more investor confidence.

  • The Vyrix IPO, which could occur before the end of 2014 and substantially boost Ampio's cash holdings.

If Ampio can achieve all four of these goals, it could be considerably undervalued at current prices. But if the Ampio drops the ball with either Optina or Ampion, investors can expect a very steep drop ahead.

Incredible growth stock to watch today

Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 24, 2013, at 1:07 AM, ltinves wrote:

    The author completely misunderstands and understates the size of the market for Ampion. Ampion was not tested against Synvisc One. Both Ampion and Synvisc One trials for OA used saline as a control. Saline is not a placebo as it does provide relief.

    The 2012 sales for all of the hyaluronic acid ("HA")products like Synvisc One were

    Synvisc One $500,000,000 USA sales

    Euflexxa $250,000,000 USA sales

    Synvisc $155,000,000 USA sales

    Total in USA alone $905,000,000

    More importantly there are 27,000,000 OA sufferers in the USA. The majority of these patients are in the severe and more severe categories. Patients are stratified according to Kellgren Lawrence scores. The most severe patients are in the K4 group. These patients have no treatment options other than knee replacement. The HA trials ( and in clinical practice) did not include the more severe K3 and all the K4 patients.


    Ampion achieved statistical significance in both the pain, WOMAC A and function, and WOMAC C.

    No other trial has ever done this. Ampion achieved a 42.3 reduction in pain.

    There are 20,000,000 patients in the USA that are K3 and K4. The K4 patients alone represent over a billion dollars in sales annually and they have nothing to treat them, except opioids.

    The American Academy of Orthopedic Surgeons said that HA products are ineffective. Better to take aspirin. That is why the current market in the USA is only a 1 billion for HA.

    The market for those patients who can't benefit from HA but can from Ampion is many billions more.

  • Report this Comment On January 06, 2014, at 3:25 PM, maurelius1999 wrote:

    The author completely discounts the management team and its past history and that of the company.

    Michael Macaluso was involved in Isolagen, another biotech that was in phase 3 trials that blew out, wasted $100 million plus and filed for bankruptcy after over promoting itself, its product and its ability to commercialize the technology. Macaluso's 'extensive entrepreneur experience" includes running a printing company, running isolagen into the ground, and being a co owner of a long distance slamming operation called Axxes.

    Dr. Clift was also involved in Isolagen. Dr. Clift 'invented' the automated cellular expansion unit that was supposedly key to commercializing the Isolagen process and which debuted at an investor conference. Otherwise known as ACE, the unit appeared to be nothing more than a non functioning prototype.

    Ampio went public in a reverse merger, which should be a red flag in and of itself since this is a back door IPO without the underwriter due diligence.

    Lots of fun related party stuff disclosed in the proxy...small accounting firm...

    what Macaluso knows about biotech can be summarized on a postage stamp.

Add your comment.

DocumentId: 2774388, ~/Articles/ArticleHandler.aspx, 4/17/2014 12:11:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...